RxDoctor Payments Data

Nicole Thurman

Family · Portland, ORNPI 1659635464

Payments from drug & device makers

$977in general payments, 2019–2025

Across 36 payments — averaging $27.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$624
  • Viiv Healthcare Company$171
  • Janssen Scientific Affairs, LLC$61
  • Johnson & Johnson$40
  • Bristol Myers Squibb$22
  • Merck$22
  • plus $37 from 2 others

What the payments were for

  • Food & beverage$977100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$977 in reported general payments places this provider in the 80th percentile of 1,130 family providers in Oregon.

See all family providers in Oregon

Medicare billing

Part B allowed, 2024
$5,300
Medicare patients
39
Services billed
95

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala528$2,207,890
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf51$253,290
DovatoDolutegravir Sodium/Lamivudine73$232,871
GenvoyaElviteg/Cob/Emtri/Tenof Alafen54$229,255
TivicayDolutegravir Sodium91$217,773
PrezcobixDarunavir/Cobicistat47$118,390
OdefseyEmtricitab/Rilpiviri/Tenof Ala30$107,952
PifeltroDoravirine38$71,979
TrulicityDulaglutide42$46,059
DescovyEmtricitabine/Tenofov Alafenam17$41,473
JardianceEmpagliflozin87$39,881
JulucaDolutegravir/Rilpivirine11$39,724
EliquisApixaban22$24,297
MounjaroTirzepatide20$22,600
Atovaquone25$9,498

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy$624$2,478,618599 claims
Viiv Healthcare CompanyDovato, Tivicay, Juluca$171$490,368175 claims
Johnson & JohnsonPrezcobix, Xarelto$40$124,87959 claims
MerckPifeltro, Januvia$22$79,98153 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,130 family providers in Oregon.

Other family in Portland

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →